The document describes various drug products from Solace Biotech that begin with the letter P. Prazoto-40 contains the active ingredient Pantoprazole which inhibits gastric acid secretion and is used to treat gastroesophageal reflux disease. Prazoto-D contains Pantoprazole and Domperidone to reduce stomach acid. Prazoto-DSR contains a sustained release formulation of Pantoprazole with Domperidone. Prazoto-IV provides Pantoprazole in an injectable formulation for intravenous use to treat gastric and duodenal ulcers.

1. Solace Biotech
Product s

2. Name of BraNds start
With alphaBet “p”

3. Prazoto- 40
Prazoto-D
Prazoto- DSR
Prazaoto- Injection
P

6. Prazoto- 40
contains
Pantoprazole
Prantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion.
Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus
caused by gastroesophageal reflux disease. Initial treatment is generally of eight weeks'
duration, after which another eight week course of treatment may be considered if
necessary It can be used as a maintenance therapy for long term use after initial response is
obtained.
This medication may affect the results of certain lab tests, such as drug screenings
(pantoprazole can cause a false positive for THC, the psychoactive component of cannabis[1
).
It has also been known to cause false positive for benzodiaze
http://www.webmd.com/drugs/drug-17633-pantoprazole+Oral.aspx?drugid=17633&drugname=pantop

7. http://www.drugs.com/pantoprazole.html
You should not use this medication if you are allergic to pantoprazole or to any other
benzimidazole medication such as albendazole (Albenza), or mebendazole (Vermox).
Pantoprazole is not for immediate relief of heartburn symptoms.
Heartburn is often confused with the first symptoms of a heart attack. Seek emergency
medical attention if you have chest pain or heavy feeling, pain spreading to the arm or
shoulder, nausea, sweating, and a general ill feeling.
Take pantoprazole for the full prescribed length of time. Your symptoms may improve
before the condition is fully treated.
Pantoprazole should not be taken together with atazanavir (Reyataz) or nelfinavir (Viracept).
Tell your doctor if you are taking either of these medications to treat HIV or AIDS.
Some conditions must be treated long-term with pantoprazole. Chronic use has caused
stomach cancer in animal studies, but it is not known if this medication would have the same
effects in humans. Talk with your doctor about your specific risk of developing stomach
cancer.
Long-term treatment with pantoprazole may also make it harder for your body to absorb
vitamin B-12, resulting in a deficiency of this vitamin. Talk with your doctor if you need
long-term pantoprazole treatment and you have concerns about vitamin B-12 deficiency.

8. Prazoto-D
Contains
Pantoprazole
Domperidone
* Pantoprazole is not recommended for children less than 12years.
* Caution should be exercised in patients with history of liver disease, any other
gastrointestinal disorders, any allergy and during pregnancy.
* Avoid prolonged usage of this medication.
* It may cause dizziness, do not drive a car or operate machinery while taking this
medication.
http://www.medindia.net/doctors/drug_information/pantoprazole_domperidone.htm

9. 3. Prevention of Nausea and Vomiting Associated With Radiotherapy, Either Total
Body Irradiation, or Single High-Dose Fraction or Daily Fractions to the Abdomen
• The recommended oral dosage is one 8-mg Onlit Tablet given 3 times a day.
• For total body irradiation , one 8-mg Onlit Tablet should be administered 1 to 2 hours
before each fraction of radiotherapy administered each day.
For single high-dose fraction radiotherapy to the abdomen , one 8-mg Onlit Tablet should
be
administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after
the first dose for 1 to 2 days after completion of radiotherapy.For daily fractionated
radiotherapy to the abdomen , one 8-mg Onlit Tablet should be
administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after
the first dose for each day radiotherapy is given.
4.Postoperative Nausea and Vomiting PONV
The recommended dosage is 16 mg given as two 8-mg OnlitTablets 1 hour before
induction
of anesthesia.
For the prevention of PONV Ondansetron can be administered orally or by intravenous or
intramuscular injection.
Ondansetron may be administered as a single dose of 4mg given by intramuscular or slow
intravenous injection at induction of anesthesia.
For treatment of established PONV a single dose of 4mg given by intramuscular or slow
intravenous injection is recommended.

10. Prazoto-DSR
Conauns
Pantoprazole
Domeridone – Sustained Release
Pantoprazole with Domperidone is used to reduce the amount of acid produced by the
stomach, to treat or prevent conditions such as heartburn, Gastritis, ulcers and GERD. For
best results, it should be taken just before a meal. It can help with the greater amount of
stomach acid that is always produced. The capsules are generally offered in the composition
of Pantoprazole 40mg & Domperidone 30 mg sustained release. Sustained release dosage
forms are designed to release a drug at a predetermined rate in order to maintain a constant
drug concentration for a specific period of time with minimum side effects. This can be
achieved through a variety of formulations, including liposomes and drug-polymer
conjugates (an example being hydrogels). Sustained release's definition is more akin to a
"controlled release" rather than "sustained".

11. Prazoto- IV( Injection)
contains
Sterile Pantaprozole Sodium
( as Lyophilized )
Prazoto-IV is indicated for the treatment of gastric ulcer, duodenal ulcer, moderate and
severe reflux oesophagitis.
DOSAGE AND ADMINISTRATION:
Route of Administration: For IV use only
MECHANISM OF ACTION:
Pantoprazole is a Proton Pump Inhibitor (PPI) that suppresses the final step in gastric acid
production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory
surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated
gastric acid secretion irrespective of the stimulus. The binding to the (H+, K+)-ATPase
results in a duration of antisecretory effect that persists longer than 24 hours for all doses
tested.